Connection Between General Practitioner's (GP's) Estimation of Cardiovascular Risk and Theoretical Calculation in France

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01039402
First received: December 24, 2009
Last updated: September 14, 2010
Last verified: September 2010
  Purpose

The purpose of this study is to evaluate connection between GP's estimation of cardiovascular risk and theoretical calculation.


Condition
Cardiovascular Risk

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Connection Between GP's Estimation of Cardiovascular Risk and Theoretical Calculation in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate connection between GP's estimation of cardiovascular risk and theoretical calculation (according to guidelines and validated scales (such as risk score profile in the Framingham Heart study or the SCORE risk estimation)) [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To estimate the number of cardiovascular risk patients, that have not been identified [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
  • To characterize those patients according to their theoretical cardiovascular risk (high, medium, low) [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
  • to reveal GP's estimation of cardiovascular risk is especially driven by LDL [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Estimated Enrollment: 13502
Study Start Date: December 2009
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Adults ≥ 50 years old

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Primary care

Criteria

Inclusion Criteria:

  • Adults 50 years old and over, visiting their GPs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01039402

  Show 277 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Pr Eric BRUCKERT APHP Paris - France, Hôpital La Pitié-Salpétriêre
Principal Investigator: Mrs Geneviève BONNELYE KantarHealth - France
  More Information

No publications provided

Responsible Party: MC MD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01039402     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2009/3
Study First Received: December 24, 2009
Last Updated: September 14, 2010
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
cardiovascular risk
France
Observational, descriptive study

ClinicalTrials.gov processed this record on July 24, 2014